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INTRODUCTION 
~2-agonists have an important role in the treatment of 
asthma alongside inhaled corticosteroids. Short-acting 
agents have been used for three decades--their fast on- 
set of bronchodilation has made them ideal for providing 
immediate relief of symptoms. During this time, how- 
ever, there has been much debate about the suitability of 
/~-agonists for regular maintenance therapy. More re- 
cently, with the introduction of agents with long-acting 
profiles, i.e. formoterol and salmeterol, it has been recog- 
nized that fi2-agonists have different pharmacological 
properties and are therefore suitable for use in different 
situations. Current guidelines recommend the use of 
short-acting ~2-agonists as first-line reliever medication 
and long-acting fi2-agonists as regular therapy for patients 
inadequately controlled on inhaled corticosteroids. 
Formoterol (Oxis ~ Turbuhaler ~) has a unique phar- 
macological profile and is both fast- and long-acting. It is 
already widely used in maintenance therapy in combina- 
tion with inhaled cortieosteroids and, with an onset of 
action similar to salbutamol, it is also suitable for use as 
needed for symptom relief. This unique profile prevents 
formoterol from being accurately placed into current 
classifications of fi2-agonists, which are based on dura- 
tion of effect, i.e. short-acting or long-acting agents. 
Long-acting agents have traditionally been seen as unsui- 
table for as-needed relief of symptoms--this is appropri- 
ate for salmeterol because it has a slow onset of effect, 
but not for formoteroI.Therefore, it may be more infor- 
mative to differentiate agents by a combination of onset 
and duration of effect. 
The presentations from a series of international work- 
shops, the Oxis ~ World Lecture Series (OWLS), which took 
place in London (February 2000), Singapore (June 2000) 
and Brussels (September 2000) form the basis for this 
supplement. The meetings, entitled '/32-agonists--from 
pharmacological properties to everyday clinical practice', 
were led and attended by key specialists from all over 
the world. The principal objective was to discuss ad- 
vances in clinical research into fl2-agonists and the inte- 
gration of this knowledge into clinical practice, with 
particular emphasis on the changing role of formoterol. 
The topics covered include the evolution of/G2-agonist 
therapy; the pharmacological profile of different ~2-ago- 
nists; clinical aspects of formoterol treatment, i.e. effi- 
cacy and safety, when used both as reliever and as 
maintenance therapy; the use of theTurbuhaler ~ device 
and, finally, the position of formoterol in relation to cur- 
rent treatment guidelines. 
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